A citation-based method for searching scientific literature

N Colombo, C Sessa, A du Bois, J Ledermann, W G McCluggage, I McNeish, P Morice, S Pignata, I Ray-Coquard, I Vergote, T Baert, I Belaroussi, A Dashora, S Olbrecht, F Planchamp, D Querleu. Ann Oncol 2019
Times Cited: 207



Jonathan Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra, Daniela Matei, Euan Macpherson, Claire Watkins, James Carmichael, Ursula Matulonis. N Engl J Med 2012
Times Cited: 1038




List of shared articles



Times cited

Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer.
M Chiappa, F Guffanti, F Bertoni, I Colombo, G Damia. Drug Resist Updat 2021
3

The systemic treatment of recurrent ovarian cancer revisited.
T Baert, A Ferrero, J Sehouli, D M O'Donnell, A González-Martín, F Joly, J van der Velden, P Blecharz, D S P Tan, D Querleu,[...]. Ann Oncol 2021
4

Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
Angeles Alvarez Secord, David M O'Malley, Anil K Sood, Shannon N Westin, Joyce F Liu. Gynecol Oncol 2021
0

Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3.
Andrew R Clamp, Domenica Lorusso, Amit M Oza, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I Weberpals, Giovanni Scambia, Alexandra Leary,[...]. Int J Gynecol Cancer 2021
1

Tumor Genotyping and Homologous Recombination Repair Gene Variants in Patients With Epithelial Ovarian Cancer: Is Pathogenic Enough?
Elena Fountzilas, Vassiliki Kotoula, Georgia-Angeliki Koliou, Michalis Liontos, Kyriaki Papadopoulou, Eleni Giannoulatou, Alexios Papanikolaou, Ioannis Tikas, Sofia Chrisafi, Davide Mauri,[...]. Front Oncol 2021
0

Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy.
Angelina Tjokrowidjaja, Michael Friedlander, Sarah J Lord, Rebecca Asher, Manuel Rodrigues, Jonathan A Ledermann, Ursula A Matulonis, Amit M Oza, Ilan Bruchim, Tomasz Huzarski,[...]. Eur J Cancer 2021
0